Scientific Articles

Vitamin B2 tablets and sunshine. Hard lenses that hold the cone back. A cornea too thin to treat. Seven things patients are commonly told about keratoconus, checked against the Second Global Consensus, in which 128 corneal experts from six continents voted on what the evidence actually supports.
Swapping the UV lamp for the sun and riboflavin drops for a vitamin B2 tablet is being promoted as a low-cost keratoconus treatment. A new ELZA study in the Journal of Refractive Surgery tested it in living eyes and found no corneal stiffening at all.
A new Die Ophthalmologie review explains ELZA-sub400 cross-linking, an individualised protocol that fits the UV dose to each cornea, making cross-linking possible in keratoconus corneas as thin as 214 µm.
ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.
A new ELZA review in Die Ophthalmologie examines the mechanisms, clinical evidence, protocol selection, and indications for PACK-CXL in infectious keratitis.
The Second Global Consensus on Keratoconus and Ectatic Diseases was published today, and ELZA played a key role in its development.
.
.